NCT01045564View on ClinicalTrials.gov

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

GSK influenza virus H5N1 vaccine 1557484A

Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm

Trial Locations (3)

20910

GSK Investigational Site, Silver Spring

30329-4018

GSK Investigational Site, Atlanta

20892-1584

GSK Investigational Site, Bethesda

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

United States Department of Health and Human Services, Center for Disease Control and Prevention, National Institutes of Health, Department of Defense

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT01045564 - Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure | Biotech Hunter | Biotech Hunter